Literature DB >> 17487746

Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.

Ryuya Yamanaka, Junpei Homma, Masakazu Sano, Naoto Tsuchiya, Naoki Yajima, Yoshikatsu Shinbo, Akira Hasegawa, Kiyoshi Onda, Ryuichi Tanaka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17487746     DOI： 10.1080/10428190701248009

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.

Authors:  Julien Cobert; Ephraim Hochberg; Nina Woldenberg; Fred Hochberg
Journal:  J Neurooncol       Date:  2009-12-18       Impact factor: 4.130

2.  GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.

Authors:  Yasuo Takashima; Momoko Hamano; Junya Fukai; Yasuo Iwadate; Koji Kajiwara; Tsutomu Kobayashi; Hiroaki Hondoh; Ryuya Yamanaka
Journal:  Sci Rep       Date:  2020-05-21       Impact factor: 4.379

3.  Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China.

Authors:  Yuankai Shi; Ying Han; Jianliang Yang; Peng Liu; Xiaohui He; Changgong Zhang; Shengyu Zhou; Liqiang Zhou; Yan Qin; Yongwen Song; Yueping Liu; Shulian Wang; Jing Jin; Lin Gui; Yan Sun
Journal:  Chin J Cancer Res       Date:  2019-02       Impact factor: 5.087
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.